Shanghai MicroPort Medical (Group) Co., Ltd.

Since the introduction in 2004, Firebird™ and Firebird2™ (introduced in 2008) have been the market leader in the Coronary Artery Disease market in China. Approximately 1.3 million Firebirds have been sold and 800 thousand patients’ live have been saved. On 28 January 2014, Firehawk® Rapamycin Target Eluting Coronary Stent has been approved for market launch by the China Food and Drug Administration (CFDA). Firehawk® is the Company's third generation internally developed drug-eluting stents used for the treatment of coronary artery stenosis and occlusion.

Contact Information

  • Add: 501 Newton Road, Z.J. Hi-Tech Park, Shanghai 201203 P.R. China
  • Tel: (86) (21) 38954600
    Fax: (86) (21) 50801305
  • Zip: 201203